How long should Tamoxifen typically be used for treatment and prophylaxis in premenopausal women?

Tamoxifen is commonly prescribed as a treatment option for both the treatment and prevention of hormone receptor-positive breast cancer in premenopausal women. The typical duration of treatment is generally recommended to be between 5 to 10 years. This duration is supported by clinical studies that have shown significant benefits in terms of reducing the risk of cancer recurrence and improving overall survival rates.

Using Tamoxifen for the recommended range of 5 to 10 years helps to ensure that the therapy is effective while also managing potential side effects and risks associated with long-term use. Prolonged exposure beyond this time frame, while it may provide additional protective benefits, can also increase the likelihood of adverse effects.

For treatment or prophylaxis decisions, medical professionals consider individual patient factors, including cancer risk profiles and personal preferences, but the 5 to 10 year window is a standard guideline based on extensive research and clinical outcomes.